# A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients )

> **NCT02964910** · PHASE4 · COMPLETED · sponsor: **Xiamen Innovax Biotech Co., Ltd** · enrollment: 475 (actual)

## Conditions studied

- Hepatitis E

## Interventions

- **BIOLOGICAL:** Recombinant Hepatitis E Vaccine (Escherichia Coli)

## Key facts

- **NCT ID:** NCT02964910
- **Lead sponsor:** Xiamen Innovax Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2017-08
- **Final completion:** 2017-12
- **Target enrollment:** 475 (ACTUAL)
- **Last updated:** 2019-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02964910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02964910, "A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients )". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02964910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*